

Full-length p53 mRNA is a frequent source of $\Delta 133p53$ and $\Delta 160p53$ protein isoforms

Maria Jose Lopez-Iniesta^{1,2}, Masatoshi Hagiwara², Marco M. Candeias^{1,3}

¹MaRCU, Graduate School of Medicine, Kyoto University

²Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University


³Department of Human Genetics, National Health Institute Dr Ricardo Jorge, Portugal



公益財団法人
大塚敏美育英奨学財団
Otsuka Toshimi Scholarship Foundation


Background

Tumor suppressor p53, considered the most extensively studied gene in the medical field, still keeps some secrets. Up to the present, human short isoforms **$\Delta 133p53$** and **$\Delta 160p53$** have been thought to be **translated** exclusively from the **short mRNA transcript**, which originates from an internal promoter at intron 4.




Results & conclusions


Q1. Can short isoforms **$\Delta 133p53$** and **$\Delta 160p53$** be translated from the full-length p53 mRNA?




Q2. Is the **translation** of these short isoforms dependent on the 5'-cap?



Q3. Does the **expression** of the short isoforms **vary** depending on **drug usage**?



Remarks



With this study we have proved that short **p53** isoforms **$\Delta 133p53$** and **$\Delta 160p53$** can be translated from the **FL transcript**.

Translation of **$\Delta 133p53$** and **$\Delta 160p53$** from FL mRNA is IRES-mediated, **5'-cap-independent**.

Drug usage changes the **expression** levels of these **isoforms**.

Understanding the expression patterns and differential regulation of **shorter p53 isoforms** is crucial as they may contribute differently to p53 associated **functions** and to the development of diseases.

If you want to know more about our lab's research...

Visit MaRCU website,
areap53.com



Check poster **3P-0189**:
Minip53, new p53 isoform that responds to DNA damage in glioblastoma cell lines
Shrutee Parkaar

Send me an e-mail!
majolopezin@gmail.com